Work

A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens

Year: 2023

Type: editorial

Abstract: Since their introduction in 1980s, proton pump inhibitors (PPI) heralded a sweeping change in the management of acid-related disorders. Their efficacy and ease to obtain have led to common use of P...

Source: Expert Opinion on Drug Metabolism & Toxicology

DOI: 10.1080/17425255.2023.2190883

Authors: Rachel Chevalier, Thomas Attard, Sara L Van Driest, Valentina Shakhnovich

Institutions: Children's Mercy Hospital, University of Missouri, Vanderbilt University Medical Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4324309735

Cites: 13

Cited by: 8

Related to: 10